Sanjay Ahuja Appointed CEO and Medical Director of Innovative Hematology
Sanjay Ahuja, Chief Medical Officer, CEO and Medical Director of Innovative Hematology, Inc., shared Innovative Hematology, Inc.‘s post on LinkedIn:
“I am deeply grateful for this opportunity, and both honored and humbled by the responsibility it carries.
As I reflect on this moment, I’m reminded that none of us walks this path alone. We stand on the shoulders of those who came before us, lean on those who walk alongside us, and have a responsibility to lift those who follow.
Thankful for the mentors, colleagues, and teams who have made this journey possible
As I look ahead, I’m inspired by the opportunity to build, to serve, and to create something that meaningfully improves the lives of our patients we are so privileged to serve.
The work continues—and the best is still ahead.”
Innovative Hematology, Inc. shared a post on LinkedIn:
“Today marks Dr. Sanjay Ahuja‘s first day as Medical Director and CEO of Innovative Hematology.
As we look ahead, our focus now is clear:
to build on the strong foundation already in place, strengthen the continuity of care our patients depend on, and position IHI for thoughtful and sustainable growth.
Stay updated with Hemostasis Today.
-
May 13, 2026, 07:35Ifeanyichukwu Ifechidere: Why DIC is the Condition That Humbles even the Most Experienced Scientists
-
May 13, 2026, 07:26Genoveva Uzunova: Why It’s Time to Close the Sex Variable Gap in Healthcare
-
May 13, 2026, 07:09Auston Cherbonneaux: Why Erythritol Just Joined the High-Hazard List
-
May 13, 2026, 06:48Akshat Jain: Transforming Sickle Cell Care With Practical Apheresis Frameworks
-
May 13, 2026, 06:35Dima Shulkin: How Neutrophil Extracellular Traps Shape ACS
-
May 13, 2026, 05:50Danny Hsu: Global Maternal VTE Awareness and Opportunities for Prevention
-
May 13, 2026, 05:50Ney Carter Borges: Clinical Cardiovascular Polygenic Risk Report for 8 Conditions
-
May 13, 2026, 05:49Kalyan Roy: A New Blood Group System Has Been Discovered
-
May 13, 2026, 05:07Azin Alizadehasl: Unraveling DIC in Cancer-Driven Coagulopathy